Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 41% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 21.5% with 36.4% net margin
- Revenue growing at 20% annually
Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3.0 billion . Key value metrics: P/E ratio 14.4, P/B ratio 3.10, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Catalyst Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX) is currently trading 41% above its Graham Number of $17.20, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 14.4x.
On financial health, CPRX shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 21.5% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.16.
StockPik's composite Value Score for CPRX is 84/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CPRX reports a high gross margin of 85.8% (sector average: 33.5%) and a strong operating margin of 43.7%.
CPRX shows revenue growing at 20% year-over-year, with earnings growing at 31%.